Calprotectin is a protein biomarker that is present in the faeces when intestinal inflammation occurs. Faecal calprotectin testing is helping to improve patient care and save money for the NHS. It prevents the need for unnecessary endoscopy procedures on many patients by screening out those with Irritable Bowel Syndrome (IBS).
The symptoms of functional disorders such as IBS and organic Inflammatory Intestinal Disease (IBD) can be very similar in presentation but are two very different medical conditions.
Historically, clinical gastroenterologists have had to use invasive endoscopy to differentially diagnose between these conditions. NICE [DG11] now recommends the use of faecal calprotectin analysis, as a first-line test, in patients presenting with gastrointestinal symptoms indicative of IBS or IBD. The test can rule out IBD and avoid the need for IBS patients to undergo endoscopy. This prevents patient stress, shortens waiting lists and cuts costs.
Calprotectin is also shown to be of value in the ongoing assessment of known IBD patients, with the biomarker concentration reflecting mucosal healing or potential relapse.
Measurement of faecal Calprotectin is considered a reliable indicator of inflammation and numerous studies show that while faecal Calprotectin concentrations are significantly elevated in patients with IBD, patients suffering from IBS do not have increased Calprotectin levels. Such increased levels are shown to correlate well with both endoscopic and histological assessment of disease activity.
The NHS Centre for Evidence-based Purchasing has conducted several reviews on calprotectin testing and its use in differentiating IBS and IBD. These reports conclude that using calprotectin assays supports improvements in patient management and offers substantial cost savings.
Faecal Calprotectin is used to help differentiate between IBS and IBD. It is also used to assess the efficacy of treatment and predict the risk of flare-ups in IBD patients.
Children often have slightly higher Calprotectin levels than adults.
The treatment aim in IBD patients is clinical remission. Mucosal healing is associated with sustained clinical remission along with reduced rates of hospitalisation and surgical resection and identifying patients likely to relapse enables their therapy to be adjusted accordingly.
Determining relapse in patients presenting with no blood in faeces prevents the need for sigmoidoscopy and enables treatment to be started earlier.
Calprotectin levels predict clinical relapse with a 90% sensitivity and 83% specificity.
Tibble et al demonstrated that amongst patients with IBD in remission, 90% with a high faecal Calprotectin level had relapsed within a year, whilst only 10% of those with a low faecal Calprotectin level relapsed within the same period.
View all Calprotectin Literature